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The missing link: A single unifying mechanism for diabetic A1c. Patients with type 1 diabetes whose intensive insulin
complications. A causal relationship between chronic hypergly- therapy produced HbA1c levels 2% lower than those
cemia and diabetic microvascular disease, long inferred from receiving conventional insulin therapy had a 76% lowervarious animal and clinical studies, has now been definitely
incidence of retinopathy, a 54% lower incidence of ne-established by data from the Diabetes Control and Complica-
phropathy, and a 60% reduction in neuropathy. A rela-tions Trial (DCCT), a multicenter, randomized, prospective,
controlled clinical study. A relationship between chronic hyper- tionship between levels of chronic hyperglycemia and
glycemia and diabetic macrovascular disease in patients with diabetic microvascular and macrovascular disease in pa-
non-insulin-dependent diabetes mellitus (NIDDM) is also sup- tients with type 2 diabetes has also been found in severalported by the Kumamoto study. How does hyperglycemia in-
studies [2–4]. Thus, hyperglycemia is the primary initiat-duce the functional and morphologic changes that define dia-
betic complications? Vascular endothelial cells are a major ing factor in the pathogenesis of diabetic complications.
target of hyperglycemic damage, but the mechanisms underly- The distinguishing characteristic of cells that have
ing this damage remain incompletely understood. Three seem- been damaged by hyperglycemia is their lack of down-
ingly independent biochemical pathways are involved in the
regulation of glucose transport when extracellular glu-pathogenesis: glucose-induced activation of protein kinase C
cose is elevated. Vascular smooth muscle cells that have(PKC) isoforms; increased formation of glucose-derived ad-
vanced glycation end products; and increased glucose flux not been damaged by hyperglycemia show an inverse
through the aldose reductase pathway. The relevance of each relationship between glucose concentration and glucose
of these three pathways is supported by animal studies in which transport measured as 2-deoxyglucose uptake. In con-pathway-specific inhibitors prevent various hyperglycemia-
trast, vascular endothelial cells, a major target of hyper-induced abnormalities. Hyperglycemia increases reactive oxy-
glycemic damage, show no significant change in glucosegen species (ROS) production inside cultured bovine aortic
endothelial cells. In this paper, we show that ROS may activate transport when glucose concentration is elevated. Thus,
aldose reductase, induce diacylglycerol, activate PKC, induce intracellular hyperglycemia appears to be the major de-
advanced glycation end product formation, and activate the
terminant of diabetic tissue damage [5].pleiotropic transcription factor nuclear factor-kappa B (NF-kB).
Intracellular hyperglycemia causes tissue damage byThese data demonstrate that a single unifying mechanism of
induction, increased production of ROS, serves as a causal link mechanisms that can be grouped into two categories.
between elevated glucose and each of the three major pathways One category of mechanisms involves repeated acute
responsible for diabetic damage. changes in cellular metabolism that are reversible when
euglycemia is restored. Another category of mechanisms
involves cumulative changes in long-lived macromole-
A causal relationship between chronic hyperglycemia cules that persist despite restoration of euglycemia.
and diabetic microvascular disease, long inferred from
These mechanisms are influenced by genetic determi-
various animal and clinical studies [1], has now been
nants of susceptibility or resistance to hyperglycemicdefinitely established by data from the Diabetes Control
damage.and Complications Trial (DCCT), a multicenter, ran-
Four major hypotheses about how hyperglycemiadomized, prospective, controlled clinical study. The
causes diabetic complications have generated a largeDCCT study demonstrated conclusively that the relative
amount of data, as well as several clinical trials basedrisks for the development of diabetic complications in-
on specific inhibitors of these mechanisms: formationcreased with increasing levels of mean hemoglobin (Hb)
of reactive oxygen species; increased activity of aldose
reductase; activation of protein kinase C (PKC) isoforms;
Key words: diabetes mellitus, hyperglycemia, protein kinase C, NF-kB. and increased formation of advanced glycation end prod-
ucts. No current unifying hypothesis links these four mecha-Ó 2000 by the International Society of Nephrology
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nisms, but either polyol pathway-induced redox changes thy, perhaps due to the low aldose reductase activity in
retinal vascular cells [10].[decreased nicotinamide adenine dinucleotide phosphate
The third mechanism by which intracellular hypergly-(reduced form) (NADPH)/nicotinamide adenine dinu-
cemia damages tissue is PKC activation. Hyperglycemiacleotide phosphate (NADP1) and increased nicotinamide
increases DAG content, in part by de novo synthesisadenine dinucleotide (reduced form) (NADH)/nicotin-
and possibly also by phosphatidylcholine hydrolysis. In-amide adenine dinucleotide (NAD1) ratios] or hypergly-
creased DAG activates PKC, primarily the b and d iso-cemia-induced formation of reactive oxygen species could
forms. Activated PKC increases the production of cyto-potentially account for all of the other biochemical ab-
kines and extracellular matrix (ECM), the fibrinolyticnormalities.
inhibitor plasminogen activator inhibitor (PAI-1), andHyperglycemia increases intracellular reactive oxygen
the vasoconstrictor endothelin-1. PKC is also a mediatorspecies (ROS) and lipid peroxidation. In aortic endothe-
of vascular endothelial growth factor activity. Theselial cells, 30 mmol/L glucose increased ROS formation
changes contribute to basement membrane thickening,[measured as dichlorofluorescein (DCF)] by 250% with-
vascular occlusion, increased permeability, and activa-in 24 hours, and resultant lipid peroxidation (measured
tion of angiogenesis [11]. ROS also activate PKC in vas-as malondialdehyde) by 330% by 168 hours. Thus, hyper-
cular endothelial cells. As ROS-producing H2O2 increases,glycemia rapidly increases intracellular ROS production
it activates PKC. The mechanism appears to involvein cells affected by diabetic complications [6].
direct or indirect activation of phospholipase D, whichThe enzyme aldose reductase converts various alde-
hydrolyzes phosphatidylcholine to produce DAG. ROShydes (such as 2-oxo-aldehydes and those derived from
could also increase DAG through increased de novolipid peroxidation) to inactive alcohols. NADPH is the
synthesis resulting from ROS inhibition of the enzymecofactor in both this reaction and also in the regeneration
glyceraldehyde phosphate dehydrogenase [12, 13].of glutathione by glutathione reductase. The activity of
The significance of this mechanism has been estab-aldose reductase is reversibly down-regulated by nitric
lished by studies of an isoform-specific PKC inhibitor inoxide modification of a cysteine residue in the enzyme’s
diabetic animals. Diabetes increased mean retinal circu-active site. ROS appear to reduce nitric oxide levels and
lation time in rats from 0.67 second to 1.40 seconds.thus may activate aldose reductase [7–9]. In a euglycemic
Treatment of diabetic rats with the PKCb inhibitor LYenvironment, oxidant stress (i.e., ROS) increases the
333531 reduced the time to 0.87 second at the highestconcentration of toxic aldehydes. At the same time, nitric
dose tested. Similarly, diabetes increased glomerular fil-oxide levels are reduced, converting aldose reductase to
tration rate (GFR) in rats from a mean of 3.0 to 4.6a higher activity form. Glutathione levels are unaffected,
mL/min. Treatment of diabetic rats with the PKCb inhib-
and the reactive aldehydes are detoxified.
itor LY 333531 normalized the mean glomerular filtra-
In a hyperglycemic environment, oxidant stress (ROS) tion rate (GFR) at the highest doses tested. Similarly,
increases, and the reactive aldehydes are then detoxi- diabetes increased the albumin excretion rate in rats
fied. However, in contrast to the euglycemic state, in- from a mean of 1.6 to 11.7 mg/day. Treatment of diabetic
creased intracellular glucose concentration results in rats with the PKCb inhibitor LY 333531 reduced the
increased enzymatic conversion of glucose to the polyal- mean albumin excretion rate to 4.9 mg/day at the highest
cohol sorbitol, with concomitant decreases in NADPH dose tested [14].
and glutathione. In cells in which aldose reductase activ- The final mechanism by which intracellular hypergly-
ity is sufficient to deplete glutathione, hyperglycemia- cemia damages susceptible tissues is by increasing the
induced oxidative stress is augmented. Sorbitol is oxi- formation of advanced glycation end products (AGEs).
dized to fructose by the enzyme sorbitol dehydrogenase AGEs can arise from autooxidation of glucose to glyoxal,
(SDH). In cells in which sorbitol dehydrogenase activity decomposition of the Amadori product to 3-deoxygluco-
is high, this may result in an increased NADH : NAD1 sone, and fragmentation of glyceraldehyde-3-phosphate
ratio. This could increase de novo synthesis of diacylglyc- to methylglyoxal. These reactive dicarbonyls react with
erol (DAG) by inhibition oxidation of triose phosphates, amino groups of proteins to form AGEs. Methylglyoxal
thereby activating PKC. and glyoxal are detoxified by the glyoxalase system. All
The effect of aldose reductase inhibition is most strik- three AGE precursors are also substrates for other re-
ing on diabetes-induced decreases in nerve conduction ductases as well [15, 16]. Intracellular production of AGE
velocity. In dogs with diabetes, conduction became sig- precursors damages target cells by three general mecha-
nificantly less than normal within 42 months [10]. Con- nisms. First, intracellular protein glycation alters protein
duction velocity in aldose reductase inhibitor-treated function. Second, ECM modified by AGE precursors has
dogs remained statistically equal to normal throughout abnormal functional properties. Third, plasma proteins
the 5-year study. In contrast, aldose reductase inhibition modified by AGE precursors bind to AGE receptors on
adjacent cells such as macrophages, thus inducing recep-had no effect on the development of diabetic retinopa-
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tor-mediated ROS production that activates nuclear fac- 85% to 90%. These include the development of retinal
acellular capillaries and retinal microaneurysms, increasedtor-kappa B (NF-kB) and expression of pathogenic gene
products, including cytokines and hormones [17]. urinary albumin excretion and mesangial fraction vol-
ume, decreased motor and sensory nerve conduction ve-An example of intracellular protein glycation is the
increase in macromolecular endocytosis in endothelial locity and action-potential amplitude, and diminished ar-
terial elasticity and increased arterial fluid filtration [17].cells by the AGE-precursor methylgloxal. Exposure to
30 mmol/L glucose increased macromolecular endocyto- It has been proposed that a potential relationship may
exist between polyol pathway-induced redox changessis by GM7373 endothelial cells stably transfected with
neo 2.2-fold. In contrast, when increased methylglyoxal and the three other biochemical mechanisms underlying
diabetic complications. In this scheme, increased glucoseaccumulation was prevented by overexpressing the en-
zyme glyoxalase I in these cells, 30 mmol/L glucose did flux through the polyol pathway could decrease the
NADPH : NADP1 ratio, thereby reducing glutathionenot increase macromolecular endocytosis [15]. An exam-
ple of matrix modification by AGE-precursors is the in- reductase activity and increasing oxidative stress. In
those cells where significant oxidation of sorbitol to fruc-creased permeability to albumin of glomerular basement
membrane modified by AGEs. Ultrafiltration of albumin tose occurs, increased sorbitol flux through this pathway
could also increase the NADH : NAD1 ratio, thereby(Js) by AGE-modified glomerular basement membrane
is significantly increased compared with ultrafiltration of blocking glycolysis at the level of triose phosphates and
increasing formation of a-glycerol phosphate, a precur-albumin by unmodified glomerular basement membrane
over a range of different filtration pressures [18]. sor of DAG. In addition, increased triose phosphate
concentrations produce more of the most potent AGE-Five AGE-binding proteins have been identified: the
receptor for advanced glycation end products (RAGE), precursor, methylgloxal. The difficulties with this at-
tempt at a unifying theory of diabetic complications isp60, p90, galectin-3, and the scavenger receptor type II.
RAGE is a novel member of the immunoglobin super- that aldose reductase activity is low in several major
target cells damaged in diabetes, such as endothelialfamily, whose ligation generates ROS and activates the
pleiotropic transcription factor NF-kB. p60 exhibits 95% cells. In addition, experimentally, aldose reductase inhib-
itors have no effect on hyperglycemia-induced increasesidentity to OST-48, a component of the oligosaccharyl-
transferase complex in microsomal membranes, and p90 in endothelial cell DAG, contrary to what is predicted
[24, 25]. An alternative unifying mechanism is hypergly-has significant sequence homology with human 80K-H,
a PKC substrate. Galectin-3, a carbohydrate-binding cemia-induced ROS production. ROS may activate aldose
reductase, induce DAG, activate PKC, induce advancedprotein, also binds AGEs. The type II macrophage scav-
enger receptor binds AGEs and mediates their uptake glycation end product formation, and activate the pleiotro-
pic transcription factor NF-kB [6–8, 12, 26, 27].by endocytosis. To date, only RAGE has actually been
shown to transduce signals initiated by AGE-ligand Glucose-induced damage in cells of arteries may be
further accelerated by insulin resistance. Insulin resis-binding. The signal transduction pathway involves the
generation of ROS, which then activate the pleiotropic tance may damage arteries indirectly by exacerbating
known risk factors for vascular damage. Insulin resis-transcription factor NF-kB [19–22].
AGE-modified protein binding to specific receptors tance alone or combined with hyperinsulinemia is associ-
ated with atherogenic changes in plasma lipoproteins,on macrophages and endothelial cells cause pathologic
changes in diabetic blood vessels by inducing the expres- increased PAI-1, and hypertension. This association has
been termed “Syndrome X” [28]. Alternatively, we havesion of pathogenic gene products. On macrophages and
mesangial cells, binding stimulates production of tumor proposed that insulin resistance in vascular cells may
promote damage by inhibiting antiatherogenic gene ex-necrosis factor a, (TNF-1) interleukin-1, insulin-like growth
factor-1, and granulocyte-macrophage colony-stimulat- pression. Selective resistance to insulin action in the pho-
sphatidyl inositol 3-kinase signaling pathway may reduceing factor at levels that increase proliferation of smooth
muscle cells and increase matrix production. On endo- antiproliferative nitric oxide production and interfere
with insulin’s inhibitory effect on TNF and angiotensinthelial cells, binding induces changes in gene expression
that are procoagulatory, and increases expression of leu- II’s stimulation of PAI-1 and intracellular adhesion mol-
ecule expression [9].kocyte-binding vascular adhesion molecule-1 [23].
The significance of AGEs as mediators of glucose- The susceptibility to damage by hyperglycemia, at
least for the kidney and retina, is determined by un-induced pathology in diabetic target tissues has been
established by using an inhibitor of AGE formation. The known genetic factors. For example, in patients with type
1 diabetes, the cumulative incidence of overt proteinuriaeffects of an AGE inhibitor (aminoguanidine) on diabetic
pathology have been investigated in retina, kidney, nerve, levels off at 27%. After 34 years of diabetes, the cumula-
tive incidence of end-stage renal disease in affected pa-and artery. In experimental animals, development of all
pathognomonic abnormalities examined was inhibited tients is 21.4%. These data suggest that only a subset of
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